论文部分内容阅读
本文对我科2010—2015年收治的肺血栓栓塞症行溶栓治疗的病人,选择低剂量重组组织纤溶酶原激活药(rtPA)50mg溶栓治疗,观察病人预后症状主要再栓塞发生的时间,发生例数及其病因。1资料与方法1.1临床资料本组为2010—2015年收治的肺血栓栓塞症行溶栓治疗病人90例,入组病例均为大面积及次大面积肺血栓栓塞症的病人,男58例,女32例,年龄21~84岁。1.2方法选择低剂量重组组织纤溶酶原激活药50mg溶栓
This article for our department from 2010 to 2015 in patients with thromboembolism thrombolytic therapy, the choice of low-dose recombinant tissue plasminogen activator (rtPA) 50mg thrombolytic therapy to observe the prognosis of patients with major re-embolization of the time , The number of cases and their causes. 1 Materials and Methods 1.1 Clinical data of the group for the 2010-2015 thrombolytic therapy of pulmonary thromboembolism in patients treated 90 cases, the patients were large and large pulmonary thromboembolism patients, 58 males, Female 32 cases, aged 21 to 84 years old. 1.2 Methods Low-dose recombinant tissue plasminogen activator 50mg thrombolytic therapy